bioAffinity Technologies (BIAF)

• Market cap: $5.92M
• 1 day: -1.17%
• 5 days: -26.92%
• 1 month: -54.76%
• 3 months: -63.46%
• 6 months: -71.21%
• Year to date: -59.58%
• 1 year: -74.67%
• 5 years: -95.42%
• 10 years: -95.42%
• Sector: Industrials
• Industry: Commercial Physical & Biological Research

About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Employees: 75

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

14% more funds holding

Funds holding: 14 [Q3] → 16 (+2) [Q4]

0.03% less ownership

Funds ownership: 3.47% [Q3] → 3.44% (-0.03%) [Q4]

49% less capital invested

Capital invested by funds: $973K [Q3] → $497K (-$475K) [Q4]